News headlines about Cellect Biotechnology (NASDAQ:APOP) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cellect Biotechnology earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.3539948127423 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Cellect Biotechnology (APOP) opened at 7.98 on Wednesday. The company’s market capitalization is $858.51 million. Cellect Biotechnology has a one year low of $2.30 and a one year high of $13.50. The stock has a 50 day moving average price of $8.06 and a 200 day moving average price of $8.06.
A number of research firms have commented on APOP. HC Wainwright reissued a “buy” rating and set a $14.00 price target (up from $12.00) on shares of Cellect Biotechnology in a report on Monday, September 25th. ValuEngine raised Cellect Biotechnology from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st.
TRADEMARK VIOLATION WARNING: This news story was reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://baseballnewssource.com/markets/cellect-biotechnology-apop-earning-somewhat-positive-news-coverage-accern-reports/1700588.html.
About Cellect Biotechnology
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Receive News & Ratings for Cellect Biotechnology Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology Ltd. and related companies with our FREE daily email newsletter.